The High Throughput Screening Facility (HTSF) has developed during the previous five years to meet a need identified for high throughput capabilities and a central resource for multiple areas of translational research. The HTSF provides screening services, including the instrumentation and expertise to develop assays, execute siRNA and small molecule screens, and support for follow-up and secondary assay development and execution. In addition, the HTSF resources are available to clinical investigators to develop and implement clinical correlate assays for clinical trials and population science studies. The automation and detection instrumentation is available to all Fox Chase Cancer Center (FGGG) researchers, providing new technologies to investigators. Instrumentation and resources available from the HTSF include: automation compatible with 96 and 384 well screening platforms, the human genome siRNA library (Thermo-Fisher Dharmacon), and small molecule libraries (approx 50,000 compounds). Duhng its period as a developing facility the HTSF has acquired resources and reagents, initiated procedures for screen execution and provided assay services and screening support. In GY 2009, the HTSF provided support to 19 peer-reviewed, funded investigators, from all five of the Center's CCSG Research Programs (Section V). This user base has developed due to the strong institutional support provided by FCCC, including $776,808 for start-up equipment, as well as $1,454,952 in operating costs (FY2005-present). This has enabled the Facility to charge back Principal Investigators, (Pis) at reduced rates to enhance usage. The combination of equipment, expertise and subsidization has converged to create a community of screeners and translational scientists by initiating collaborative relationships among PI laboratories as well as between facilities, while in the process creating additional demand for HTSF support. The HTSF is a unique resource, as it combines services to a diverse group of investigators and collaboration among multiple, facilities. This allows the HTSF to act as a hub for translational science by making the most of the Center's resources in high throughput technology, traditional benchwork and clinical approaches.

Public Health Relevance

The HTSF provides a suite of services designed to accelerate the identification of new tools and therapeutic targets for cancer. Discoveries made through utilization of the screening and assay development tools provided by the HTSF will impact areas such as development of innovative probes for basic research, biomarker discovery and novel therapeutic approaches.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475337
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$58,033
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952

Showing the most recent 10 out of 1280 publications